David F. Lehmann

712 total citations
37 papers, 464 citations indexed

About

David F. Lehmann is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, David F. Lehmann has authored 37 papers receiving a total of 464 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pharmacology, 7 papers in Pediatrics, Perinatology and Child Health and 7 papers in Pharmacology. Recurrent topics in David F. Lehmann's work include Pharmacogenetics and Drug Metabolism (6 papers), Pharmaceutical studies and practices (5 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). David F. Lehmann is often cited by papers focused on Pharmacogenetics and Drug Metabolism (6 papers), Pharmaceutical studies and practices (5 papers) and Health Systems, Economic Evaluations, Quality of Life (4 papers). David F. Lehmann collaborates with scholars based in United States, Canada and Switzerland. David F. Lehmann's co-authors include Joseph J. Medicis, Panagiotis A. Konstantinopoulos, Roy Guharoy, Nancy Newman, Adrienne Smith, William Darko, Dongliang Wang, Patricia D. Franklin, William Eggleston and Christine A. Stidley and has published in prestigious journals such as Brain Research, CHEST Journal and Journal of Medicinal Chemistry.

In The Last Decade

David F. Lehmann

33 papers receiving 441 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David F. Lehmann United States	13	166	73	67	59	59	37	464
Busba Chindavijak Thailand	9	104 0.6×	63 0.9×	40 0.6×	49 0.8×	52 0.9×	27	395
Scott Bryson United Kingdom	11	131 0.8×	49 0.7×	70 1.0×	66 1.1×	29 0.5×	19	396
Paul K. L. Chin New Zealand	15	126 0.8×	88 1.2×	69 1.0×	40 0.7×	40 0.7×	58	624
Simone van Kralingen Netherlands	8	147 0.9×	79 1.1×	58 0.9×	34 0.6×	27 0.5×	10	515
Steven J. Kovacs United States	12	70 0.4×	129 1.8×	63 0.9×	43 0.7×	57 1.0×	19	469
Arthur A. Schuna United States	13	85 0.5×	33 0.5×	61 0.9×	40 0.7×	27 0.5×	19	573
Brian G. Hardy Canada	12	153 0.9×	54 0.7×	50 0.7×	46 0.8×	33 0.6×	15	522
Anna Wiela−Hojeńska Poland	12	113 0.7×	44 0.6×	66 1.0×	72 1.2×	48 0.8×	42	416
Miguel Gil Spain	13	119 0.7×	54 0.7×	168 2.5×	39 0.7×	73 1.2×	37	643
W. P. Geus Netherlands	13	167 1.0×	63 0.9×	92 1.4×	26 0.4×	27 0.5×	22	598

Countries citing papers authored by David F. Lehmann

Since Specialization

Citations

This map shows the geographic impact of David F. Lehmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David F. Lehmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David F. Lehmann more than expected).

Fields of papers citing papers by David F. Lehmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David F. Lehmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David F. Lehmann. The network helps show where David F. Lehmann may publish in the future.

Co-authorship network of co-authors of David F. Lehmann

This figure shows the co-authorship network connecting the top 25 collaborators of David F. Lehmann. A scholar is included among the top collaborators of David F. Lehmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David F. Lehmann. David F. Lehmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Lehmann, David F., et al.. (2018). Magnesium Sulfate Treatment Correlates With Improved Neurological Function in Posterior Reversible Encephalopathy Syndrome (PRES). The Neurologist. 23(2). 65–66. 5 indexed citations

2.

Kufel, Wesley D., Adam Zayac, David F. Lehmann, & Christopher D. Miller. (2016). Clinical Application and Pharmacodynamic Monitoring of Apixaban in a Patient with End‐Stage Renal Disease Requiring Chronic Hemodialysis. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 36(11). e166–e171. 16 indexed citations

3.

Lehmann, David F., et al.. (2016). A Case of Methadone-Induced Anasarca and Non-Cardiogenic Pulmonary Edema. CHEST Journal. 150(4). 526A–526A.

4.

Bolli, Martin H., Stefan Abele, Magdalena Birker, et al.. (2013). Novel S1P₁ Receptor Agonists – Part 1: From Pyrazoles to Thiophenes. Journal of Medicinal Chemistry. 56(23). 9737–9755. 18 indexed citations

5.

Lehmann, David F.. (2012). The Metabolic Rationale for a Lack of Cross-reactivity Between Sulfonamide Antimicrobials and Other Sulfonamide-containing Drugs. Drug Metabolism Letters. 6(2). 129–133. 10 indexed citations

6.

Lehmann, David F.. (2012). The Metabolic Rationale for a Lack of Cross-reactivity Between Sulfonamide Antimicrobials and Other Sulfonamide-containing Drugs. Drug Metabolism Letters. 6(2). 129–133. 7 indexed citations

7.

Lehmann, David F. & Daniel Sitar. (2011). The Seduction of Biomarkers in the Practice of Medicine and the Tyranny of Power in the Drug Approval Process: Lessons From Niacin. The Journal of Clinical Pharmacology. 51(11). 1496–1498. 2 indexed citations

8.

Lehmann, David F.. (2010). Teaching From Catastrophe: Using Therapeutic Misadventures From Hydromorphone to Teach Key Principles in Clinical Pharmacology. The Journal of Clinical Pharmacology. 51(11). 1596–1602. 2 indexed citations

9.

Lehmann, David F., Roy Guharoy, Joseph J. Medicis, et al.. (2007). Every Error a Treasure: Improving Medication Use with a Nonpunitive Reporting System. The Joint Commission Journal on Quality and Patient Safety. 33(7). 401–407. 23 indexed citations

10.

Lehmann, David F., Christine M. Stork, & Roy Guharoy. (2006). Hospital Pharmacology: An Alternative Model for Practice and Training in Clinical Pharmacology. The Journal of Clinical Pharmacology. 46(8). 850–854. 8 indexed citations

11.

Arp, Jacqueline, Michael Rieder, Bradley L. Urquhart, et al.. (2005). Hypersensitivity of HIV-1-Infected Cells to Reactive Sulfonamide Metabolites Correlated to Expression of the HIV-1 Viral Protein Tat. Journal of Pharmacology and Experimental Therapeutics. 314(3). 1218–1225. 17 indexed citations

12.

Konstantinopoulos, Panagiotis A. & David F. Lehmann. (2005). The Cardiovascular Toxicity of Selective and Nonselective Cyclooxygenase Inhibitors: Comparisons, Contrasts, and Aspirin Confounding. The Journal of Clinical Pharmacology. 45(7). 742–750. 53 indexed citations

13.

Darko, William, Joseph J. Medicis, Adrienne Smith, Roy Guharoy, & David F. Lehmann. (2003). Mississippi Mud No More: Cost‐Effectiveness of Pharmacokinetic Dosage Adjustment of Vancomycin to Prevent Nephrotoxicity. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 23(5). 643–650. 63 indexed citations

14.

Lehmann, David F., Joseph J. Medicis, & Patricia D. Franklin. (2003). Polymorphisms and the Pocketbook: The Cost‐Effectiveness of Cytochrome P450 2C19 Genotyping in the Eradication of Helicobacter pylori Infection Associated with Duodenal Ulcer. The Journal of Clinical Pharmacology. 43(12). 1316–1323. 27 indexed citations

15.

Marraffa, Jeanna M., et al.. (2003). Life‐Threatening Bradycardia: The Clinical Relevance of Propoxyphene Inhibition of CYP2D6. Clinical Pharmacology & Therapeutics. 73(2).

16.

Lehmann, David F.. (2000). Observation and Experiment on the Cusp of Collaboration: A Parallel Examination of Clinical Pharmacology and Pharmacoepidemiology. The Journal of Clinical Pharmacology. 40(9). 939–945. 4 indexed citations

17.

Lehmann, David F.. (2000). Enzymatic Shunting: Resolving the Acetaminophen‐Warfarin Controversy. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 20(12). 1464–1468. 27 indexed citations

18.

Lehmann, David F., Andrew Liu, Nancy Newman, & Donald C. Blair. (1999). The Association of Opportunistic Infections with the Occurrence of Trimethoprim/Sulfamethoxazole Hypersensitivity in Patients Infected with Human Immunodeficiency Virus. The Journal of Clinical Pharmacology. 39(5). 533–537. 14 indexed citations

19.

Lehmann, David F., et al.. (1997). Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. Clinical Pharmacology & Therapeutics. 62(2). 225–229. 28 indexed citations

20.

Lehmann, David F., P D Holohan, & Donald C. Blair. (1996). Comparisons of Oxidative Metabolism and Reductive Capacity in Sulfonamide‐Tolerant and ‐Intolerant Patients with Human Immunodeficiency Virus. The Journal of Clinical Pharmacology. 36(12). 1149–1153. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact